BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27354621)

  • 21. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy.
    Song S; Rudra S; Hasselle MD; Dorn PL; Mell LK; Mundt AJ; Yamada SD; Lee NK; Hasan Y
    Cancer; 2013 Jan; 119(2):325-31. PubMed ID: 22806897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic implication of retrocrural lymph node involvement revealed by (18)F-FDG PET/CT in patients with uterine cervical cancer.
    Im HJ; Yoon HJ; Lee ES; Kim TS; Kim JY; Chung JK; Kim SK; Park SY
    Nucl Med Commun; 2014 Mar; 35(3):268-75. PubMed ID: 24253568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study.
    Rose PG; Ali S; Watkins E; Thigpen JT; Deppe G; Clarke-Pearson DL; Insalaco S;
    J Clin Oncol; 2007 Jul; 25(19):2804-10. PubMed ID: 17502627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Curative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastases.
    Kim JY; Kim JY; Kim JH; Yoon MS; Kim J; Kim YS
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):741-7. PubMed ID: 22898382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment results and prognostic factors for advanced squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy.
    Taguchi T; Nishimura G; Takahashi M; Komatsu M; Sano D; Sakuma N; Arai Y; Yamashita Y; Shiono O; Hirama M; Sakuma Y; Ishitoya J; Hata M; Ogino I; Oridate N
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):837-43. PubMed ID: 23959463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematological parameters during concurrent chemoradiotherapy as potential prognosticators in patients with stage IIB cervical cancer.
    Cho O; Noh OK; Oh YT; Chang SJ; Ryu HS; Lee EJ; Chun M
    Tumour Biol; 2017 Feb; 39(2):1010428317694306. PubMed ID: 28222668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study.
    Guo Q; Sun Y; Kong E; Rao L; Chen J; Wu Q; Zhang T; Liu N; Li M; Sun L
    Medicine (Baltimore); 2020 Mar; 99(11):e19372. PubMed ID: 32176061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Gynecol Oncol; 2012 Aug; 126(2):211-6. PubMed ID: 22555110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors.
    Kim YB; Cho JH; Keum KC; Lee CG; Seong J; Suh CO; Kim GE
    Gynecol Oncol; 2007 Jan; 104(1):58-63. PubMed ID: 16919718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.
    Rose PG; Java J; Whitney CW; Stehman FB; Lanciano R; Thomas GM; DiSilvestro PA
    J Clin Oncol; 2015 Jul; 33(19):2136-42. PubMed ID: 25732170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors.
    Mabuchi S; Morishige K; Isohashi F; Yoshioka Y; Takeda T; Yamamoto T; Yoshino K; Enomoto T; Inoue T; Kimura T
    Gynecol Oncol; 2009 Dec; 115(3):482-7. PubMed ID: 19783286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparisons of survivals and toxicities between young and elderly patients with cervical cancer treated with definitive radiotherapy or concurrent chemoradiotherapy.
    Wang W; Liu X; Meng Q; Zhang F; Hu K
    Taiwan J Obstet Gynecol; 2019 May; 58(3):364-369. PubMed ID: 31122526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications.
    Chen SW; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yang SN; Lin FJ
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1370-7. PubMed ID: 16979836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.
    Schefter TE; Winter K; Kwon JS; Stuhr K; Balaraj K; Yaremko BP; Small W; Gaffney DK
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1179-84. PubMed ID: 22342094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ib2 to IVa squamous cell carcinoma of the uterine cervix].
    Li XF; Li YH; Gao YN; Li CL; Yue HZ; Xu G; Li DM; Su X
    Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):763-7. PubMed ID: 24406134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Impact of Escalating Relative High-dose-rate Intracavitary Brachytherapy Dose in Stage IIB Cervical Cancer.
    Cho O; Noh OK; Oh YT; Chang SJ; Chun M
    Anticancer Res; 2017 Jan; 37(1):327-334. PubMed ID: 28011510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sarcopenia Is an Important Prognostic Factor in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy.
    Kiyotoki T; Nakamura K; Haraga J; Omichi C; Ida N; Saijo M; Nishida T; Kusumoto T; Masuyama H
    Int J Gynecol Cancer; 2018 Jan; 28(1):168-175. PubMed ID: 29040185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nomograms predicting survival and patterns of failure in patients with cervical cancer treated with concurrent chemoradiotherapy: A special focus on lymph nodes metastases.
    Wang W; Liu X; Meng Q; Zhang F; Hu K
    PLoS One; 2019; 14(4):e0214498. PubMed ID: 30986236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.
    Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP
    Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective phase I-II trial of helical tomotherapy with or without chemotherapy for postoperative cervical cancer patients.
    Schwarz JK; Wahab S; Grigsby PW
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1258-63. PubMed ID: 20932657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.